Clinical trials: Chronic Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
- Conditions
- Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
- Trial name
- NCT00547066
- Testing
- veltuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Primary Immune Thrombocytopenia
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP).
- Trial name
- NCT05621330
- Testing
- QL0911
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hepatitis C, Chronic
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent…
- Trial name
- NCT00516321
- Testing
- eltrombopag
- Where
- 191 sites in United States, Australia and 23 more
- Volunteers
- 687 people
- Sponsor
- GlaxoSmithKline
Thrombocytopenia; Drugs, Chronic Liver Disease
Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
In this study, investigators aimed to evaluate the efficacy of Avatrombopag in thrombocytopenic patients with chronic liver disease undergoing an elective invasive procedure through a prospective, non-randomized controlled…
- Trial name
- NCT04915287
- Testing
- Avatrombopag maleate, Platelet transfusion, Medicine
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Chinese PLA General Hospital
Primary Immune Thrombocytopenia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons.
- Trial name
- NCT05422365
- Testing
- Intravenous immunoglobulin (IVIG), 10% solution for infusion
- Where
- 12 sites in Ukraine
- Volunteers
- 32 people
- Sponsor
- Biopharma Plasma LLC
Idiopathic Thrombocytopenic Purpura
Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag
This is a single-center, prospective, controlled study with one eltrombopag treatment group and 2 control groups, one on standard steroid treatment, and another one untreated.
- Trial name
- PLATEFUN (NCT00888901)
- Testing
- eltrombopag, corticosteroids (Aprednislon)
- Volunteers
- 30 people
- Sponsor
- Ingrid Pabinger, MD
Vaccine Adverse Reaction
Genomics and COVID-19 Vaccine Adverse Events
Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS)…
- Trial name
- NCT05212792
- Testing
- COVID-19 vaccines
- Where
- Canada
- Volunteers
- 6,325 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Persistent or Chronic ITP
Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP
Thrombopoietin-receptor agonists (Tpo-RAs) have profoundly changed the management of ITP. However, today, there are no international recommendations concerning the long-term use of these costly, potentially pro-thrombotic agents…
- Trial name
- STOP-AGO (NCT03119974)
- Testing
- Tpo-RA discontinuation
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenic Purpura
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP).
- Trial name
- NCT00168038
- Testing
- Immunoglobulin Intravenous (Human)
- Where
- 17 sites in Germany, Italy and 4 more
- Volunteers
- 58 people
- Sponsor
- CSL Behring
Chronic Thrombocytopenia
Cerebral Dysfunction in Chronic ITPwith High Risk of Serious Bleeding Excluding Intracranial Hemorrhage.
Intracranial hemorrhage despite being rare, several chronic ITP patients experience moderate to severe behavioral problems including learning difficulties, memory affection .These changes could be due to the presence of minute…
- Trial name
- NCT01764971
- Testing
- IQ assessment and visual- motor assessment, EEG,brain imaging
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Chronic Primary Immune Thrombocytopenia (ITP)
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients with Chronic Primary Immune Thrombocytopenia
- Trial name
- NCT06004856
- Testing
- Orelabrutinib
- Where
- 45 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Immune Thrombocytopenia
Eltrombopag in Chronic ITP
This study aims to evaluate the efficacy of eltrombopag on the platelet count in pediatric patients with chronic immune thrombocytopenia.
- Trial name
- NCT04102033
- Testing
- Eltrombopag
- Volunteers
- 20 people
- Sponsor
- Assiut University
Immune Thrombocytopenia
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety…
- Trial name
- NCT02566603
- Testing
- PRTX-100
- Where
- 16 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Protalex, Inc.
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03195010
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Thrombocytopenia Related to Chronic Liver Disease
Effect of Rifaximin on Thrombocytopenia in Patients With HCV-Related Liver Cirrhosis
Cirrhosis is a common complication of chronic hepatitis C virus (HCV) infection in Egypt. Thrombocytopenia (TP) is the most common cytopenia in patients with cirrhosis and may be associated with variceal bleeding, rebleeding…
- Trial name
- NCT07791940
- Testing
- Rifaximin (drug)
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Fayoum University Hospital
Purpura, Thrombocytopenic, Idiopathic
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia.
- Trial name
- NCT03275454
- Testing
- BIVV009 6.5 grams, BIVV009 7.5 grams
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Bioverativ, a Sanofi company
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia…
- Trial name
- myOpportunITy1 (NCT04200456)
- Testing
- Rozanolixizumab
- Where
- 29 sites in United States, Bulgaria and 14 more
- Volunteers
- 33 people
- Sponsor
- UCB Biopharma SRL
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura
- Trial name
- NCT00415532
- Testing
- Medical Standard of Care for ITP, Romiplostim
- Volunteers
- 234 people
- Sponsor
- Amgen
ITP - Immune Thrombocytopenia, Chronic ITP
Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.
- Conditions
- ITP - Immune Thrombocytopenia, Chronic ITP, Refractory ITP
- Trial name
- NCT05613296
- Testing
- Fostamatinib
- Where
- 21 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University